Related Experiment Video
Updated: May 7, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Variations in antibiotic use in late preterm and term newborns from 2012 to 2020: a nationwide population-based
Johan Gyllensvärd1,2, Marie Studahl3,4, Lars Gustavsson3,4
1Department of Paediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden johan.gyllensvard@gu.se.
Objective:
To quantify regional and unit variations in antibiotic use during the first week of life, incidence of early-onset sepsis (EOS) and mortality in late-preterm and term newborns in Sweden.
Design:
A nationwide cohort study.
Setting:
The Swedish Neonatal Quality Register, a register of all newborns admitted for neonatal care in Sweden.
Patients:
All late-preterm and term newborns (≥34 weeks' gestation) admitted to a neonatal unit from 1 January 2012 to 31 December 2020.
Main Outcome Measures:
The proportion of antibiotic use, incidence of EOS and mortality in late-preterm and term newborns.
Results:
Out of 1 025 515 newborns, 19 286 neonates (1.9%) received antibiotics with a 2-fold to 5-fold variation across regions (1.3%-3.0%) and units (0.9%-4.3%). Duration of antibiotic therapy (median) varied across regions from 7-10 days for infants with EOS, and 4-7 days for infants with no sepsis. Incidence of EOS ranged from 0.33 to 0.93 per 1000 live births between regions. The number of infants treated per EOS case varied 2-fold to 15-fold across regions (22-39) and units (7-113). All-cause mortality and EOS-associated mortality ranged across regions from 0.21 to 0.54 per 1000 live births and 0.0 to 34.9 (3 of 86 newborns) per 1000 infants with EOS.
Conclusions:
This nationwide study revealed wide variations in antibiotic use and in the number of infants treated per EOS case. The results indicate a disproportionate antibiotic use in relation to the incidence of EOS. This emphasises the need for future efforts to minimise unwarranted antibiotic use.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Excretion
Development of Human Microbiota
Development of the Oral Microbiota
Clinical Significance of Antibiotic Resistance

